3Waterer GW, Wunderink RG. Increasing threat of gram-negative bacteria[J]. Crit Care Med, 2001, 29, 4(Suppl): N75-81
4Mathai D, Lewis M T, Kugler KC, et al. Antibacterial activity of 41 antimicrobi als tested against over 2733 bacterial isolates from hospitalized patients with p neumonia: Results from the SENTRY antimicrobial surveillance program[J]. Di agn Microbiol Infect Dis, 2001, 39(2): 105-116
5Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive ca re units[J]. Crit Care Med, 2001, 29, 4(Suppl): N64-68
6Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care[J]. Drugs, 2000, 59(3): 653-680
7Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5000 patients treated with meropenem[J]. Scand J Infect Dis, 1999, 31(1): 3-10
8Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures i n seriously ill infected patients receiving antibiotics: experience with imipene m/cilastatin[J]. Am J Med, 1988, 84(5): 911-918
9Wong VK, Wright HT Jr, Ross LA, et al. Imipenem/cilastatin treatment of bacte rial meningitis in children[J]. Pediatr Infect Dis J, 1991, 10(2): 122-125
10Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their us e in bacterial meningitis[J]. J Antimicrob Chemother, 2000, 45(1): 5-7
